Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Oncophage vitespen: Interim Phase I/II data

Interim data from an open-label, investigator-sponsored Phase I/II trial of Oncophage showed

Read the full 122 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE